Permanent LDR implants in treatment of prostate cancer;Brachyterapia LDR w leczeniu raka gruczołu krokowego

Wspolczesna Onkologia

Volumn 13, Issue 6, 2009, Pages 316-329

  Skowronek, Janusz ^a   Kanikowski, Marek ^a   Zwierzchowski, Grzegorz ^a   Chicheł, Adam ^a  

^a GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

LDR brachytherapy; Permanent implants; Prostate cancer; Radioactive isotope; Seeds

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103; RADIOISOTOPE;

ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LOW ENERGY RADIATION; META ANALYSIS; PROSTATE; PROSTATE CANCER; SYSTEMATIC REVIEW;

EID: 75649091846     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99.
2. Garbaulet A, Potter R, Mazeron JJ, Meertens H, Van Limbergen E. The GEC ESTRO Handbook of Brachytherapy, Brussels 2002, Chapter 20, 473-480.
3. Leibel SA, Phillips TL. Textbook of Radiation Oncology. 2nd Edition 2004, Chapter 45; 988-1000.
4. Zelefsky MJ, Yamada Y, Cohen GJ, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 65-70.
5. Guedea F, Aguilo F, Polo A, et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radioth Oncol 2006; 80: 57-61.
6. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radioth Oncol 2000; 57: 315-21.
7. Kanikowski M, Skowronek J, Kubaszewska M, Chicheł A, Milecki P. Permanent implants in treatment of prostate cancer. Rep Pract Radioth Oncol 2008; 3: 150-67.
8. Machtens S, Baumann R, Hagemann J, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24: 289-95.
9. Morton JD, Peschel RE. Iodine-125 implants versus external beam radiation therapy for stages A2, B, C prostate cancer. Int J Radiat Oncol Biol Phys 1988; 14: 1153-57.
10. Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology 1998; 51: 884-889; discussion 889-90.
11. Pasteau O. Traitment du cancer de la prostate per le Radium. Rev Malad Nutr 1911; 363-367.
12. Denning CL. Carcinoma of the prostate seminal vesicles treated with Radium. Surg Gynecol Obstet 1922; 34: 99-118.
13. Holm HH, Juul N, Pedersen JF, et al. Transperineal I-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 283-86.
14. Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with I-125 implantation. Int J Radiat Oncol Biol Phys 1991; 21: 537-47.
15. Morton JD, Peschel RE. Iodine-125 implants versus external beam therapy for stages A2, B and C prostate cancer. Int J Radiat Oncol Biol Phys 1988; 14: 1153-57.
16. Blasko JC, Radge H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostate carcinoma using transrectal ultrasound and template guidance. Endocurietherapy Hyperthermia Oncology 1987; 3: B1-B9.
17. Kanikowski M, Skowronek J, Milecki P, Kubaszewska M, Chicheł A. Brachyterapia HDR raka gruczołu krokowego. Urol Pol 2007; 2: 5-11.
18. Merrick GS, Butler WM, Galbreath RW, et al. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002; 60: 98-103.
19. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 2002; 60 (3 Suppl 1): 39-44; discussion 44.
20. Stock RG, Stone NN. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy 2002; 1: 2-10.
21. Randy V, Heysek, MD. Modern Brachytherapy for treatment of prostate cancer. Cancer Control Jul 2007; 3: 131-38.
22. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997; 37: 565-9.
23. Porter AT, Blasko JC, Grimm PD, et al. Brachytherapy for Prostate Cancer. Cancer J Clin 1995; 45: 165-78.
24. Freeman ML, Goldhagen P, Sierra E, Hall EJ. Studies with encapsulated Iodine-125 sources. Int J Radiat Oncol Biol Phys 1982; 8: 1335-61.
25. Whitmore WF. Interstitial implantation of the prostate: 10 year results. In: Hilaris B, Nori D (eds.). Brachytherapy Update 1986. Syllabus of the Postgraduate Course Jointly Sponsored by the Brachytherapy Service, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, and the Brachytherapy Oncology Association. Memorial Sloan-Kettering Cancer Center, New York 1986, pp. 67-77.
26. King CR. LDR vs HDR brachytherapy for localized prostate cancer - the view from radiobiological models. Brachytherapy 2002; 1: 219-26.
27. Sharkey J, Chovnick SD, Behar RJ, et al. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 2000; 14: 343-50.
28. Wallner K, Merrick G, True L, et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 2005; 75: 307-10.
29. Sherertz T, Wallner K, Merrick G, et al. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy. Cancer J 2004; 10: 301-6.
30. Orio P, Wallner K, Merrick G, et al. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys 2007; 67: 342-6.
31. Chen Z, Deng J, Roberts K, Nath R. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds. Med Phys 2006; 33: 968-75.
32. Murphy MK, Piper RK, Greenwood LR, Mitch MG, Lamperti PJ, Seltzer SM, Bales MJ, Phillips MH. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys 2004; 31: 1529-38.
33. Smith RP, Beriwal S, Komanduri K, Gibbons E, Benoit R. Planning based on postneedle volume with early dosimetric assessment is beneficial for Cesium-131 permanent prostate seed implantation. Brachytherapy 2008; 7: 237-41.
34. Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications. Cancer J 2004; 10: 170-4.
35. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004; 171: 1098-104.
36. Radge H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 2001; 54: 739-47.
37. Prada PJ, Hevia M, Juan G, et al. I-125 low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years. Arch Esp Urol 2005; 58: 213-26.
38. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004; 64: 754-9.
39. Battermann JJ. J-125 implantation for localized prostate cancer: the Utrecht University experience. Radiother Oncol 2000; 57: 269-72.
40. Stone NN, Stock RG. Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Urol 2005; 66: 119-23.
41. Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ. Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy 2004; 3: 71-7.
42. Merrick GS, Wallner KE, Butler WM, Galbreath RW, Allen ZA, Adamovich E, True L. Brachytherapy aged < or = 54 years with clinically localized prostate cancer. BJU Int 2006; 98: 324-8.
43. Merrick GS, Butler WM, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 2002; 8: 322-7.
44. Bladou F, Salem N, Simonian-Sauve M, et al. Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience. Prog Urol 2004; 14: 345-52.
45. Merrick GS, Butler WM, Wallner K, et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 2002; 60: 104-8.
46. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57: 645-53.
47. Stock RG, Stone NN, De Wyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996; 77: 2386-92.
48. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007; 67: 57-64.
49. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61: 32-43.
50. Mc Elveen TL,Waterman FM, Hayeon K, Dicker AP. Factors predicting for urinary incintinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 57: 1395-404.
51. Salem N, Simonian-Sauve M, Rosello R, et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: a phase 2 study. Radiother Oncol 2003; 66: 159-66.
52. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 2006; 64: 825-34.
53. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostato-urethral-rectal fistula after prostate brachytherapy. Cancer 2000, 15: 2085-91.
54. Wallner K, Blasko J, Dattoli MJ. Prostate Brachytherapy Made Complicated. 1st ed. Seattle, Wash: Smart Medicine; 1997.
55. Shah JN, Ennis RD. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. Int J Radiat Oncol Biol Phys 2006; 64: 817-24.
56. Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 893-902.
57. Wallner K, Roy J, Zelefsky M, et al. Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994; 30: 405-9.
58. Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125-Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995; 153: 1020-5.
59. Blank L, Gonzalez DG, de Reijke TM, Dobhoiwala NF, Koedooder K. Brachytherapy with transperineal 125-Iodine seeds for localized prostate cancer. Radiother Oncol 2000; 57: 307-13.
60. Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000; 57: 273-8.
61. Norderhaug I, Dahl O, Hoisaeter PA, Heikkila R, Klepp O, Olsen DR, Kristiansen IS, Waehre H, Bjerklund Johansen TE. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectivness. Eur Urol 2003; 44: 40-6.